Incyte Corporation
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for ...
Latest News
3 days ago · benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For FridayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
3 days ago · seekingalpha.com
Incyte: Upgrading To Hold After ESMO Closed The Valuation GapI upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.
3 days ago · zacks.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
3 days ago · seekingalpha.com
Incyte Corporation (INCY) Q3 2026 Earnings Call TranscriptIncyte Corporation (INCY) Q3 2026 Earnings Call Transcript
3 days ago · marketbeat.com
What Incyte (INCY) Said on Its Q3 Earnings CallIncyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.
4 days ago · zacks.com
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
4 days ago · zacks.com
Incyte (INCY) Reports Q3 Loss, Beats Revenue EstimatesIncyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
6 days ago · seekingalpha.com
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs TranscriptIncyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
6 days ago · marketbeat.com
Incyte Highlights Promising Early Data for '890 and '734 in GI CancersIncyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”
6 days ago · zacks.com
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyINCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove INCY